Pharmaceuticals

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has entered into a collaboration agreement with Pfizer Inc. (NYSE: PFE) under which Pfizer will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single...

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that the first patient has been dosed in Japan in a Nippon Kayaku sponsored Phase 1 study of apaziquone in bladder cancer. The Phase 1 study is required by the local regulatory authorities and is designed to enroll up to 6 patients and...

Pfizer Inc. (PFE) recently expanded its collaboration agreement with Santaris Pharma A/S for the development and commercialization of ribonucleic acid (RNA) -targeted medicines which have been identified using Santaris' Locked Nucleic Acid (LNA) Drug Platform. Santaris is a clinical-stage...

Pfizer Inc. (PFE) recently expanded its collaboration agreement with Santaris Pharma A/S for the development and commercialization of ribonucleic acid (RNA) -targeted medicines which have been identified using Santaris' Locked Nucleic Acid (LNA) Drug Platform. Santaris is a clinical-stage...

Amarin Corporation plc (Nasdaq: AMRN) today announced that it intends to offer for sale its American Depositary Shares in an underwritten public offering.

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced today, during its previously announced guidance call, that it expects to achieve its 2010 net revenues guidance of $147 million to $167 million with anticipated, unaudited net revenues in the mid-$150 million range. The company also said it...

Amarin (NASDAQ: AMRN) announces a share offering today. Shares are down in post-market on the news. Book-running managers include Jefferies and Leerink Swann, alongside a co-leading manager Canaccord Genuity.

http://day-trading-the-stock-market.blogspot.com/ VPRO is UP 490% on this news today, on all time record Volume!... (RTTNews) - Spectrum Pharmaceuticals Inc. (SPPI), a biotechnology company... [[ This is a content summary only. Visit my website for full links, other content, and more...

Shares of Forest Laboratories (NYSE: FRX) are higher on the session by 0.81%, currently trading at $31.61. The stock has been moving largely lower over the past two months and is currently consolidating between the 50-day and 200-day moving averages. Options traders are buying calls on the name...

When the Chicago Board Options Exchange (CBOE) initiated options trading in 1973, options were available on exactly 16 stocks.  These days, there are more than 3,000 stocks, indexes, and exchange-traded funds (ETFs) with available options.  Option traders surveying the options-investing landscape...

Forest Laboratories, Inc. (FRX) and Almirall recently announced positive top line data on their chronic obstructive pulmonary disease (COPD) candidate, aclidinium bromide. Results were presented from a pivotal phase III study (ATTAIN) that compared the safety and efficacy of aclidinium bromide (...

Forest Laboratories, Inc. (FRX) and Almirall recently announced positive top line data on their chronic obstructive pulmonary disease (COPD) candidate, aclidinium bromide. Results were presented from a pivotal phase III study (ATTAIN) that compared the safety and efficacy of aclidinium bromide (...

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office has issued U.S. Patent 7,863,249 which covers additional dosage forms of fidaxomicin. This patent further strengthens Optimer's patent protection for fidaxomicin. The newly issued patent...

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has completed the acquisition of Théramex, Merck KGaA's European-based women's health business.